Skip to main content

Myfembree News

Myovant Sciences and Pfizer Receive U.S. FDA Approval of Myfembree, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

BASEL, Switzerland and NEW YORK, [August 05, 2022] (GLOBE NEWSWIRE) – Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has...

FDA Approves Myfembree as the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

BASEL, Switzerland and NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) – Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Uterine Leiomyomata / Fibroids, Endometriosis

Myfembree patient information at Drugs.com